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ABSTRACT The four dengue virus serotypes (DENV1 to 4) cause dengue, a major
public health problem worldwide. Individuals exposed to primary DENV infections
develop serotype-specific neutralizing antibodies, including strongly neutralizing an-
tibodies targeting quaternary epitopes. To date, no studies have measured the levels
and kinetics of serum antibodies directed to such epitopes among populations in re-
gions where dengue is endemic. Here, we use a recombinant DENV4 (rDENV4/3-
M14) displaying a major DENV3 type-specific quaternary epitope recognized by hu-
man monoclonal antibody 5J7 to measure the proportion, magnitude, and kinetics
of DENV3 type-specific neutralizing antibody responses targeting this epitope. Pri-
mary DENV3 sera from 30 individuals in a dengue hospital-based study in Nicaragua
were studied 3, 6, 12, and 18 months post-infection, alongside samples collected an-
nually 1 to 4 years post-primary DENV3 infection from 10 individuals in a cohort
study in Nicaragua. We found substantial individual variation in the proportion of
DENV3 type-specific neutralizing antibody titers attributed to the 5J7 epitope (range,
0 to 100%), with the mean significantly increasing from 22.6% to 41.4% from 3 to
18 months. We extended the transplanted DENV3 5J7 epitope on the virion (rDENV4/
3-M16), resulting in increased recognition in several individuals, helping define the
footprint of the epitope. However, 37% and 13% of the subjects still showed little to
no recognition of the 5J7 epitope at 3 and 18 months, respectively, indicating that
one or more additional DENV3 type-specific epitopes exist. Overall, this study dem-
onstrates how DENV-immune plasma from populations from areas of endemicity,
when coupled with structurally guided recombinant viruses, can help characterize
the epitope-specific neutralizing antibody response in natural DENV infections, with
direct implications for design and evaluation of dengue vaccines.
IMPORTANCE The four serotypes of dengue virus cause dengue, a major public
health burden worldwide, yet it has been challenging to develop a vaccine that is
safe and equally effective against all four serotypes. More in-depth characterization
of natural human neutralizing antibody responses is needed to identify determinants
of protective antibody responses to all DENV serotypes. Here, we use hospital and
cohort studies in a region where dengue is endemic to assess the proportion and ki-
netics of the DENV3 neutralizing antibody response directed to a quaternary epitope
on DENV3 recognized by strongly neutralizing human monoclonal antibody 5J7,
which was transplanted into a DENV4 backbone. We show that many individuals
Received 9 July 2017 Accepted 17 August
2017 Published 19 September 2017
Citation Andrade DV, Katzelnick LC, Widman
DG, Balmaseda A, de Silva AM, Baric RS, Harris E.
2017. Analysis of individuals from a dengue-
endemic region helps define the footprint and
repertoire of antibodies targeting dengue virus
3 type-specific epitopes. mBio 8:e01205-17.
https://doi.org/10.1128/mBio.01205-17.
Editor Diane E. Griffin, Johns Hopkins
Bloomberg School of Public Health
Copyright © 2017 Andrade et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Eva Harris,
eharris@berkeley.edu.
RESEARCH ARTICLE
crossm
September/October 2017 Volume 8 Issue 5 e01205-17 ® mbio.asm.org 1
recognized the 5J7 epitope, but to various degrees over time, suggesting that addi-
tional DENV3-specific epitopes likely exist. Thus, characterization of epitope-specific
neutralizing antibody responses in natural DENV infections can help define the foot-
print and repertoire of antibodies directed to DENV3 type-specific epitopes, with im-
plications for dengue vaccine development.
KEYWORDS dengue virus, natural infection, neutralizing antibodies, quaternary
epitope, repertoire, serotype-specific
Dengue is the most prevalent mosquito-borne viral disease in humans, caused byinfection with four antigenically distinct serotypes of dengue virus (DENV1 to 4), an
enveloped, positive-sense RNA flavivirus. A range of clinical manifestations can occur
during DENV infection, from undifferentiated illness and classic dengue fever (DF) to
the most severe forms, dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS),
characterized by plasma leakage, shock, and potentially death (1). One of the hallmarks
of dengue is the fact that sequential infections with different serotypes can be either
protective or pathogenic. While antibodies elicited by primary infection usually confer
lifelong protection against the homologous serotype, cross-reactive neutralizing re-
sponses can wane over time. In the event of a secondary DENV infection, it is thought
that the risk of severe disease may be increased via pre-existing cross-reactive weakly
neutralizing or non-neutralizing antibodies that facilitate virus entry into target Fc
receptor-bearing cells (2–5). Given this risk factor, it is imperative that vaccines induce
protective immunity to all 4 serotypes simultaneously.
The DENV envelope (E) protein is the major target of neutralizing antibodies (6), and
its ectodomain is comprised of three domains: EDI, EDII, and EDIII. E facilitates virus
attachment to host cells and subsequent fusion with the endosomal membrane. Recent
findings have shown that potently neutralizing human monoclonal antibodies (hMAbs)
are directed to complex quaternary epitopes present only on the E protein as assem-
bled on the dengue virion, not as the recombinant monomer (recE) (7–10). Within this
class of highly neutralizing hMAbs is 5J7, which was isolated from a donor with a history
of primary DENV3 infection (7). Cryo-electron microscopy (cryo-EM) studies of the 5J7
hMAb showed that a single Fab molecule binds three distinct E proteins on the surface
of the virion—the EDI/EDII hinge region of one E monomer and domains II and III of two
adjacent E proteins—although it is less clear whether contact points in all three
monomers are essential for neutralization potency (9). Subsequent studies employed a
reverse-genetics approach to transplant the core of the quaternary epitope targeted by
5J7 into a DENV1 backbone to create an rDENV1/3 chimeric virus, which was partially
sensitive to neutralization by the hMAb 5J7 (11). Importantly, when administered
prophylactically, 5J7 was shown to reduce the viral load in a mouse model infected with
DENV3 or rDENV1/3 (11). Based on the characterization of the DENV2 type-specific MAb
2D22, a different chimera, rDENV4/2, was created by transplanting the DENV2 EDIII onto a
DENV4 backbone (12). The DENV2-specific antibody response in polyclonal sera of individ-
uals who experienced a natural primary DENV2 infection or were immunized with a
monovalent live attenuated DENV2 vaccine tracked with the DENV2 type-specific quater-
nary structure epitope(s) on the rDENV4/2 virus (12). These observations demonstrate the
utility of chimeric DENV viruses as tools for tracking epitope-specific neutralizing antibody
responses in immune sera following DENV infection or vaccination.
In the present study, we used two recombinant DENV4 strains with expanded
transplants of the 5J7 quaternary epitope to measure the level and kinetics of neutral-
izing antibodies directed to this epitope following natural primary DENV3 infection in
Nicaragua (13) up to 4 years postinfection. Our results show that the 5J7 epitope is
either moderately or highly targeted by DENV3 type-specific neutralizing antibodies by
63 and 87% of the individuals analyzed at 3 and 18 months, respectively, and the
proportion of the DENV3 neutralizing response attributable to the partial 5J7 epitope
increases over time. Our results also suggest that the DENV3 antibody repertoire
contains other type-specific neutralizing epitope(s) yet to be characterized. Our analysis
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of the recognition of a quaternary DENV epitope in a population living in a region
where dengue is endemic serves as a model for measuring the fine specificity of
antibodies to DENV after natural infection or vaccination.
RESULTS
Study participants. Thirty patients who were enrolled for suspected dengue between
2010 and 2011 at the Nicaraguan national pediatric reference hospital, Hospital Infantil
Manual de Jesús Rivera (HIJMR), were selected for analysis of plasma collected 3, 6, 12, and
18 months post-infection. All patients were laboratory confirmed as DENV3 positive by
reverse transcription-PCR (RT-PCR) and/or virus isolation. All experienced a primary DENV
infection, with 20/30 (67%) manifesting disease as DF and 10/30 (33%) classified as DHF. In
addition, 10 individuals participating in a long-term pediatric cohort study who experi-
enced a primary DENV3 infection between 2009 and 2010 and manifested disease as DF
were chosen to analyze plasma samples 1 to 4 years post-illness.
Longitudinal analysis of DENV-specific neutralizing antibodies following pri-
mary DENV3 infection. Following primary DENV infection, a durable serotype-specific
neutralizing response can be detected years after exposure (14). To determine whether
the 5J7 epitope is recognized by the DENV3 type-specific antibody response in a setting
where dengue is endemic, neutralization assays were performed with primary DENV3
plasma collected 3 and 18 months post-infection and the rDENV4/3-M14 virus display-
ing the partial 5J7 epitope (D. Widman, E. Young, U. Nivarthi, S. R. Royal, J. Swanstrom,
L. Y. Boyd, K. Debbink, M. Begley, A. M. de Silva, W. B. Messer, and R. Baric, unpublished)
(Fig. 1A). Sigmoidal dose-response curves representative of one primary DENV3 infec-
FIG 1 Neutralizing antibody titers to the chimeric rDENV4/3-M14 virus and parental DENV3 and DENV4 viruses 3 and 18 months post-primary DENV3 infection.
(A) Ribbon diagram of the DENV E trimer (domains I, II, and III in red, yellow, and blue, respectively), showing amino acid residues within the 5J7 epitope
spanning the A, B, and B= monomers (purple and teal spheres); the residues represented by the teal spheres were transplanted into a DENV4 backbone, creating
the rDENV4/3-M14 virus. (B) As in panel A, but the residues represented by the teal spheres were transplanted into a DENV4 backbone to create the
rDENV4/3-M16 virus. (C and D) The raw antibody titration data were fitted with a four-parameter sigmoidal dose-response curve to estimate the 50%
neutralizing antibody titer (NT50) to the rDENV4/3-M14 and parental viruses DENV3 and DENV4 in plasma samples 3 and 18 months postinfection, respectively.
(E) Geometric mean of the NT50 values to the rDENV4/3-M14 and parental viruses of DENV3 and DENV4 in plasma samples 3 and 18 months postinfection. Data
are representative of two independent experiments processed in duplicate for each plasma sample. The NT50 values were compared by two-way ANOVA (n 
30). ***, P  0.001; ****, P  0.0001.
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tion show neutralization of the rDENV4/3-M14 virus at 3 and 18 months post-infection
at levels close to parental DENV3 at the later time point (Fig. 1C and D). As expected,
in all subjects, primary DENV3 plasma strongly neutralized DENV3, with titers signifi-
cantly higher than those to DENV4 virus (Fig. 1E). The neutralizing titers to the parental
strain UNC 3001 and the infecting DENV3 Nicaraguan strain were similar at both time
points (see Fig. S1 in the supplemental material), as both are members of DENV3
genotype III (15). Plasma from most individuals neutralized the rDENV4/3-M14 virus,
and some neutralized it at levels similar to DENV3 (Fig. 1E). This indicates that DENV3
type-specific neutralizing antibodies in human DENV3-immune plasma recognized the
5J7 amino acid residues transplanted into the DENV4 backbone. The longitudinal
analysis showed a significant increase in the neutralizing titers to the rDENV4/3-M14 at
18 months (P 0.001), while the neutralizing titers to the parental viruses did not show
significant variation between the time points analyzed (Fig. 1E).
Correlation between neutralizing antibody titers to rDENV4/3-M14 and DENV3
at 3 and 18 months post-primary DENV3 infection. Following primary infection, a
type-specific response to the infecting serotype and a cross-reactive response to
heterologous DENV serotypes is developed (7). In individuals who experienced a
primary DENV3 infection, the correlation between the DENV3 50% neutralizing anti-
body titer (NT50) and the DENV4 cross-reactive NT50 in plasma was not significant at 3
and 18 months post-infection (Fig. 2A and B). To investigate how the rDENV4/3-M14
virus neutralizing antibody titers track with the DENV3 response, correlation analyses
between rDENV4/3-M14 and DENV3 NT50 values were performed at 3 and 18 months
post-infection. At both time points analyzed, this correlation was significant (Fig. 2C and
D). Thus, the increased positive correlation between DENV3 and rDENV4/3-M14, com-
pared to the correlation between DENV3 and DENV4, is due to inclusion of the 5J7
epitope transplant in the DENV4 backbone.
Proportion and kinetics of the DENV3 type-specific neutralizing response
attributable to the 5J7 epitope. The proportion of the DENV3 type-specific response
FIG 2 Correlation analysis between DENV3 and DENV4 or rDENV4/3-M14 neutralizing antibody titers
over time. (A and B) Correlation between DENV3 NT50 and DENV4 NT50 at 3 and 18 months following
primary DENV3 infection, respectively. (C and D) Correlation between DENV3 NT50 and rDENV4/3-M14
NT50 at 3 and 18 months following primary DENV3 infection, respectively. Data are representative of two
independent experiments performed in duplicate for each plasma sample (n  30). Pearson correlation
coefficients (r) were calculated between the pairs of NT50 values. Linear regression lines are shown.
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attributable to the 5J7 epitope recognition was measured as (rDENV4/3-M14 NT50 
DENV4 NT50)/(DENV3 NT50  DENV4 NT50), the ratio between rDENV4/3-M14 titers and
DENV3 NT50 from which the cross-reactive component (DENV4 NT50) had been sub-
tracted. The mean proportion of DENV3 type-specific response targeted to the 5J7
epitope was 22.6% at 3 months post-infection, and at 18 months post-infection, the
proportion significantly increased to 41.4% (P 0.0184) (Fig. 3A). The proportions were
not significantly different between individuals who experienced DF versus DHF (see
Fig. S2 in the supplemental material).
To visualize the proportions of the DENV3 neutralizing antibody response attribut-
able to cross-reactive neutralization (DENV4 NT50) or the 5J7 epitope (rDENV4/3-M14
NT50 not explained by DENV4 NT50), we plotted the ratios of DENV4 NT50 to DENV3
NT50 and rDENV4/3-M14 NT50 to DENV3 NT50, where the percentage of the DENV3
neutralizing antibody response is represented on the y axis (Fig. 3B and C). The 30
individuals are aligned in an ascending order of proportion of the DENV3 response
explained by rDENV4/3-M14 at 18 months. It is evident that, at both 3 and 18 months,
there was extensive variability in the amount to which the DENV3 response is explained
by 5J7 or cross-reactive neutralization. Further, there was variation by individual in
changes in neutralizing antibody responses over time, with most individuals having an
increasing proportion of the DENV3 response attributable to the 5J7 epitope, while
several lost 5J7 recognition (Fig. 3C).
FIG 3 Proportion and kinetics of the DENV3 type-specific neutralizing antibody response attributable to the 5J7 epitope. (A) The proportion of the DENV3
type-specific response directed to the 5J7 epitope obtained with 3- and 18-month post-infection samples. Results for 3 and 18 months (n 30) were compared
by paired t test, where * represents P  0.05. (B and C) Proportion of the rDENV4/3-M14 and DENV4 neutralizing antibody response relative to DENV3 NT50,
where the y axis represents 100% of the DENV3 NT50 values at 3 and 18 months post-infection, respectively. Individual codes are ordered by the proportion
of DENV3 attributable to rDENV4/3-M14 observed at 18 months. (D) Individual trajectories of the proportion of the DENV3 type-specific response directed to
the 5J7 epitope at 3 and 18 months (n  30). (E) Pie chart representing the percentage of individuals who displayed a constant, decreased, or increased
proportion of the rDENV4/3-M14 DENV3 response between 3 and 18 months post-primary DENV3 infection (n  30). (F) Antigenic cartography map generated
from NT50. The antigenic cartography map positions viruses (closed circles [rDENV4/3-M14, DENV3, and DENV4]) and plasma (open squares) as points, with the
distance between each virus and plasma derived from its respective neutralization titer (see Materials and Methods). Each grid square corresponds to a 2-fold
dilution in the neutralization titer. Each open square represents one of the 30 plasma samples analyzed.
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As the prevalence of this type-specific epitope among individuals living in regions
where dengue is endemic is an important guide for vaccine design, the individual
variation of the proportion was further analyzed. The proportion of the DENV3 neu-
tralizing antibody response directed to the 5J7 epitope ranged from 0 to 97% at
3 months and from 6 to 100% at 18 months post-infection across the 30 individuals
studied (Fig. 3A to C). The proportions of the DENV3 neutralizing response attributable
to the 5J7 epitope were defined as low (0 to 10%), moderate (10 to 30%), and high
(above 30%). At 3 months, 57% (17/30) showed inexistent to low recognition of the 5J7
epitope, 13% (4/30) displayed moderate recognition, and 30% (9/30) displayed high
recognition of the 5J7 epitope. At 18 months, 13% (4/30), 47% (14/30), and 40% (12/30)
of the individuals displayed low, moderate, and high recognition of the 5J7 epitope,
respectively. Matched-pair analysis enabled assessment of the change of the proportion
in each individual over time (Fig. 3D). Using 1 standard deviation of the average of the
proportions at 3 and 18 months as the criterion to define change, 50% (15/30) of the
individuals displayed an increase in the proportion over time, while 37% (11/30)
showed no alteration and 13% (4/30) had a decreased proportion (Fig. 3E).
Next, we analyzed the data using antigenic cartography, where the NT50 was treated
as a “distance” between antisera and rDENV4/3-M14 as well as its parental viruses. A
convergent pattern over time was observed, with rDENV4/3-M14 and DENV3 moving
toward each other at 18 months post-primary DENV3 infection and DENV4 virus staying
about the same distance from the primary DENV3 anti-sera (Fig. 3F). This indicates
greater antigenic similarity between DENV3 and rDENV4/3-M14 as recognized by the
primary infection antisera at the later time point, with the antibody response becoming
increasingly specific to the 5J7 epitope over time.
Trajectories of the rDENV4/3-M14, DENV3, and cross-reactive neutralizing
responses.While the cross-reactive neutralizing antibody response has been described
to wane over time (7), recent studies in settings where dengue is endemic have
described the maintenance of cross-reactive titers, potentially due to “boosting” by
homotypic or heterotypic reinfection that fell short of the antibody threshold for a new
infection (16, 17). To investigate whether the constant, increased, or decreased pro-
portion of the neutralizing antibody titers targeting the 5J7 epitope between 3 and
18 months is associated with the change in magnitude of homologous and heterolo-
gous titers, samples collected at 6 and 12 months from a subset of individuals (n  12)
were used for neutralization assays to rDENV4/3-M14 and all DENV serotypes (DENV1 to
4) (Fig. 4; see Fig. S3 in the supplemental material). In this analysis, in addition to
DENV4, the cross-reactive titers as averages of anti-DENV1, 2, and 4 titers were plotted.
As an example of a constant proportion between 3 and 18 months, one subject (Fig. 4A)
FIG 4 Trajectories of neutralizing antibody responses 3, 6, 12, and 18 months post-primary DENV3 infection. The neutralizing
antibody titers to rDENV4/3-M14, DENV3, DENV4, and the overall cross-reactive titers (geometric mean of DENV1, DENV2, and
DENV4 NT50 values) from 12 individuals were analyzed. (A) rDENV4/3-M14 titers follow similar trajectory to DENV3 titers in an
individual with a constant proportion of the 5J7 response. (B) Increase of rDENV4/3-M14 titers between 3 and 6 months, with
parallel decay of cross-reactive titers, indicates affinity maturation in an individual who displayed an increased proportion of
the 5J7 response. (C) Increase in rDENV4/3-M14 titers between 12 and 18 months indicates possible homotypic reexposure in
an individual with an increased proportion of the 5J7 response. (D) Increase in cross-reactive titers between 12 and 18 months
indicates possible heterotypic reexposure in an individual who displayed a decreased proportion of the 5J7 response over
time.
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displayed rDENV4/3-M14 titers that followed similar kinetics to the DENV3 NT50 at 3, 6,
12, and 18 months, while the cross-reactive titers decayed over time. This pattern was
observed in 42% (5/12) of the individuals analyzed. As an illustration of an increased
proportion, subject 1228 (Fig. 4B) showed an increase in DENV3 and rDENV4/3-M14
titers between 3 and 6 months in parallel with a slight decrease of cross-reactive titers;
one case (8%) with this pattern was seen. Another example of increased titers from 3
to 18 months is shown with subject 1231 (Fig. 4C), where the increase of DENV3 and
rDENV4/3-M14 titers is observed at the later time points—between 12 and 18 months.
This pattern, observed in 33% (4/12) of the subjects, suggests a possible homotypic
boost, whereby reinfection with DENV3 may have occurred (18), as the effect is only
seen in the homologous titers (Fig. 4C). Finally, the pattern of decreased proportion is
observed in subject 1513 (Fig. 4D), where an increase in neutralizing titers to the
heterologous serotypes is seen at the later time points—between 12 and 18 months—
which could indicate heterotypic boosting. This pattern was observed in 17% (2/12) of
the individuals analyzed.
Proportion of the DENV3 neutralizing response targeted to the 5J7 epitope
years after infection. To test whether the durability of the DENV3 neutralizing
antibody response targeted to the 5J7 epitope is maintained beyond 18 months
post-infection, primary DENV3 plasma samples collected up to 4 years after infection in
a long-term cohort study were analyzed. While the rDENV4/3-M14 neutralizing titers
did not change across the years (Fig. 5A), the proportion trended toward an increase
between year 1 and year 2 after infection (Fig. 5B). From year 1 through year 4, the
mean proportions were 8, 25, 29, and 34%, respectively, across the 10 individuals
analyzed (Fig. 5C). The individual trajectories of the proportion indicate variations of 0
to 0.26, 0 to 0.80, 0 to 0.87, and 0 to 0.89 at years 1 to 4 (Fig. 5C). The long-term analysis
of the titers to the rDENV4/3-M14 virus indicates that the response to the 5J7 epitope
is stable and durable.
rDENV4 virus containing a larger footprint of the 5J7 epitope region. To test
whether some individuals were refractory to the rDENV4/3-M14 virus due to the
inclusion of the 5J7 epitope transplant with contact sites on 2 DENV3 E monomers, as
opposed to 3 monomers (9), a second chimeric virus was generated (Widman et al.,
unpublished). This chimeric virus, designated here rDENV4/3-M16, contains the ex-
panded 5J7 epitope transplant to encompass all three monomers (Fig. 1B). Plasma
samples from all subjects were tested against the new rDENV4/3-M16 virus to deter-
mine whether the entire structurally defined footprint of the 5J7 epitope confers a gain
of neutralization compared to the rDENV4/3-M14 virus (Fig. 6; see Fig. S4 in the
supplemental material). The neutralizing antibody titers due to rDENV4/3-M16 were
slightly higher than those of rDENV4/3-M14 at 3 and 18 months post-infection, but
not significantly so (Fig. 6A). The expansion of the quaternary 5J7 epitope in the
rDENV4/3-M16 virus in individuals who presented a moderate or high degree of
recognition of the rDENV4/3-M14 virus did not result in a significant increase of the
proportion of the DENV3 response attributable to the 5J7 epitope at either time
point analyzed (Fig. 6B). However, in individuals who displayed low neutralization
of the rDENV4/3-M14 virus at 3 months (n  17), a gain of neutralization to the
rDENV4/3-M16 virus was observed in 6 individuals at 3 months post-infection
(Fig. 6C). At 18 months, 4 individuals who displayed low neutralization of rDENV4/
3-M14 (n  8) gained neutralization to the rDENV4/3-M16 virus (Fig. 6C). However,
the fact that a number of individuals still did not recognize the 5J7 epitope at
3 months (n  11) and 18 months (n  4) even in an expanded structure suggests
that other DENV3 type-specific neutralizing epitopes contribute to the DENV3-
specific epitope repertoire.
DISCUSSION
Defining the antibody repertoire in natural DENV infections and vaccination is
critical to understanding the quality of neutralizing antibody responses in vivo. Isolation
of hMAbs from DENV-immune individuals is one approach, which has greatly advanced
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FIG 5 Proportion of the DENV3 type-specific neutralizing response targeted to the 5J7 epitope up to
4 years after infection in a cohort study design. (A) Neutralizing titers to the rDENV4/3-M14 virus from
year 1 through year 4 post-primary DENV3 infection in a cohort study setting. (B) The ratio of the 5J7
epitope neutralizing antibody response (rDENV4/3-M14) to that of the parental DENV3 was analyzed
from 1 to 4 years after primary DENV3 infection. (C) Individual trajectories of the DENV4/3-M14/DENV3
proportions from year 1 through year 4 post-primary DENV3 infection. Data are representative of two
independent experiments processed in duplicate for each plasma sample. The NT50 and the proportion
of the 5J7 response were compared by one-way ANOVA (n  10); no significant differences were
observed.
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FIG 6 Neutralizing titers and proportion of the DENV3 response attributable to the 5J7 amino acid
residues contained in the rDENV4/3-M14 and rDEV4/3-M16 viruses 3 and 18 months post-primary DENV3
(Continued on next page)
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the field (7–10, 19, 20); however, the next critical step is studying human polyclonal sera
from individuals living in regions where dengue is endemic to analyze the prevalence
of specific epitopes of interest over time. Our findings on the prevalence and durability
of a DENV3 type-specific epitope in a population of dengue endemicity up to 4 years
after infection indicate that the 5J7 epitope is an important epitope within a larger
DENV3 repertoire that requires further study. In addition, our study provides insights
regarding the footprint of the epitope and demonstrates that chimeric viruses repre-
sent a powerful tool for mapping type-specific responses following natural infection at
the population level.
The recognition of a quaternary DENV2 epitope transplant in a chimeric virus by
polyclonal sera has been previously demonstrated in rhesus macaque DENV-immune
sera and human DENV-immune sera from travelers and vaccinees (12). The successful
transplantation of the amino acids residues contained within the 5J7 epitope into a
DENV4 backbone provides an important tool for identification of antigenic sites specific
to polyclonal neutralizing antibodies following natural DENV3 infection. A recent study
demonstrated that the 5J7 MAb neutralizes the rDENV4/3-M16 virus more efficiently
than rDENV4/3-M14 and that returned travelers’ sera partially tracked with the rDENV4/
3-M14 and showed increased neutralizing antibody responses to the rDENV4/3-M16
virus (Widman et al., unpublished). Here, we show that large numbers of human plasma
samples from a population living in a region where dengue is endemic validate the
footprint of the 5J7 epitope.
Following a primary DENV infection, an increasingly type-specific response over time
is described in sera of individuals living in areas of nonendemicity (21) and returned
travelers who experienced DENV infection (7). We found that while the parental DENV3
titers did not change over time, the neutralizing response to the rDENV4/3-M14 virus
increased from 3 to 18 months. This suggests that the DENV3 type-specific response
recognizing the 5J7 epitope is enriched/selected months after infection. Supporting
evidence that the proportion of the DENV3 neutralizing response directed to the 5J7
epitope increases over time is that antigenic cartography maps show convergence of
the rDENV4/3 and parental DENV3 viruses from 3 to 18 months.
This increase in specificity could reflect the evolution and diversity of the antibody
repertoire due to stochastic events in the germinal center and mutations during affinity
maturation following infection. Memory B cells and long-lived plasma cells develop
from naïve B cells and undergo affinity maturation during several months after infec-
tion (22, 23). The improved recognition of the 5J7 epitope at 18 months could suggest
the presence of viral antigens in peripheral organs that may sustain affinity maturation
of the epitope over time. However, contrary to Zika virus (24), West Nile virus (25),
Japanese encephalitis virus (26), tick-borne encephalitis virus (27), and Ebola virus (28),
to our knowledge no studies have detected DENV in peripheral sites months after
infection. Therefore, the gain of neutralization to the 5J7 epitope from 6 to 18 months
may not be attributed to ongoing affinity maturation months after infection triggered
by persistence of DENV antigens.
The levels of cross-reactive antibodies are thought to decay over time in regions of
nonendemicity (21). However, the trajectory of cross-reactive titers at 3, 6, 12, and
18 months post-infection revealed an increase in NT50 titers in a subset of plasma
FIG 6 Legend (Continued)
infection. (A) Neutralizing antibody titers to rDENV4/3-M14 and to the chimeric virus with a larger
footprint of the 5J7 epitope (rDENV4/3-M16) in primary DENV3 plasma 3 and 18 months postinfection
(n  30). (B) Proportion of the DENV3 neutralizing response attributable to the 5J7 amino acid residues
transplanted into the DENV4 backbone in the rDENV4/3-M14 and rDENV4/3-M16 viruses 3 and
18 months post-primary DENV3 infection (n  30). (C) Representation of the number of individuals who
strongly recognize the rDENV4/3-M14 and rDENV4/3-M16 viruses or individuals who are refractory to
rDENV4/3-M14 virus and only recognize the rDENV4/3-M16 virus at 3 and 18 months postinfection. The
criteria for “low rDENV4/3-M14” or “low rDENV4/3-M16” was 0 to 10% of the DENV3 neutralizing response
due to the 5J7 epitope, whereas “moderate/high rDENV4/3-M14” or “moderate/high rDENV4/3-M16” was
defined as a proportion higher than 10%. The NT50 and the proportion of the 5J7 response were
compared by two-way ANOVA (n  30), where * represents P  0.05 and ** represents P  0.01.
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samples analyzed. This finding is consistent with a previous study by our group
demonstrating a modest increase in the magnitude and cross-reactivity of the neutral-
izing antibody response following primary DENV infection in Nicaragua (16). The
observation of “boosts” in neutralizing antibody titers suggests that reinfection with the
homologous serotype or possibly low-level heterotypic infection may have occurred.
These findings are consistent with another longitudinal study in Thailand, which also
demonstrated an increase in cross-reactive neutralizing antibody titers over time (17).
In the light of these findings, reexposure to DENV may be an important factor
modulating the long-term antibody response. As such, it may also affect the serotype-
specific epitope repertoire following DENV infection. For instance, reexposure to ho-
motypic virus, consistent with the epidemiology of DENV in our cohort study in
Nicaragua, where one serotype predominantly circulates for several years at a time,
could help explain the increase in the proportion of the neutralizing antibody response
to the 5J7 epitope over time. On the other hand, boosting of cross-reactive titers
between 6 and 18 months could explain the loss of rDENV4/3 recognition at 18 months
observed in a few individuals.
While only a small fraction (3%) of the DENV-specific memory B cell population
produces potent neutralizing antibodies (29), we showed that the 5J7 epitope is a
substantial target of neutralizing antibodies in DENV3-immune plasma months and up
to 4 years post-infection. As the 5J7 epitope transplant was expanded to include
contact sites on 3 rather than 2 E monomers, the number of individuals who recognized
the 5J7 epitope increased. Overall, as most individuals recognized the epitope either
partially or fully, this provides evidence that the 5J7 epitope is an important component
of the DENV3 type-specific neutralizing repertoire in human populations. Furthermore,
these studies demonstrate how analysis of human populations can help define the
footprint of an epitope of interest.
However, that the remaining primary DENV3 plasma samples did not gain neutral-
ization to even the chimeric virus displaying a larger footprint of the 5J7 epitope
suggests that neutralizing antibodies may target other DENV3 type-specific epitopes or
an epitope overlapping with the 5J7 site. Furthermore, the abundant cross-reactive
weakly neutralizing antibodies in polyclonal serum may compete with a minor sub-
population of potently neutralizing antibodies targeting these quaternary epitopes
through steric interference. Our data provide compelling evidence that the DENV3
type-specific neutralizing antibody repertoire contains additional epitopes. In fact,
multiple type-specific neutralizing epitopes exist for other DENV serotypes, as reported
for DENV1 (10, 20) and DENV4 (30). In addition, in the context of a polyclonal response,
binding of antibodies to one specific epitope may result in changes in the accessibil-
ity of a different epitope due to alternative conformations of the E protein (31). As
previously shown in EDIII (32), variations in the E sequence across DENV3 strains may
also affect recognition and neutralization of the 5J7 epitope. Similarly, a high degree of
individual variation in antibody epitope repertoire has also been observed in sera of
individuals naturally infected or vaccinated with yellow fever virus (33) and tick-borne
encephalitis virus (34).
In summary, the differential recognition of the 5J7 epitope among individuals could
suggest (i) variability of the antibody repertoire within the host, (ii) the critical need for
additional amino acid residues spanning the three E protein monomers contained
within the 5J7 epitope that were not transplanted into the original chimeric rDENV4/
3-M14 virus or even a greater expansion of the epitope(s) (rDENV4/3-M16), and/or (iii)
the existence of other epitopes in the DENV3 type-specific repertoire. This is the first
large-scale study demonstrating that human plasma from a population living in an area
where dengue is endemic can validate and help define the footprint of a quaternary
epitope. Further, our results strongly suggest that 5J7 epitope is an important compo-
nent of a larger DENV3 type-specific neutralizing epitope repertoire. Moreover, the use
of chimeric viruses as a molecular tool to decipher the neutralizing response in a
human population has a direct impact on guiding vaccine development and measure-
ment of type-specific response following DENV infection.
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MATERIALS AND METHODS
Ethics statement. The dengue hospital-based study and the Pediatric Dengue Cohort Study were
approved by the Institutional Review Boards of the University of California, Berkeley, and the Nicaraguan
Ministry of Health. Parents or legal guardians of the subjects enrolled in these studies provided written
informed consent, and participants 6 years of age and older provided assent.
Study population. (i) Dengue hospital-based study. Study enrollment took place in the Nicara-
guan national pediatric reference hospital, Hospital Infantil Manual de Jesús Rivera (HIMJR). Children
between 6 months and 14 years old suspected of dengue (7 days of illness) were eligible to participate
in the hospital study, as described previously (35). Laboratory-confirmed dengue cases were classified by
severity using a computerized algorithm that compiled all clinical data meeting each criterion for dengue
fever (DF), dengue hemorrhagic fever (DHF), or dengue shock syndrome (DSS), as detailed in the 1997
WHO guidelines (1, 35). Based on these guidelines, 20 individuals were classified as DF, while 10
experienced DHF. Plasma samples were collected in the acute (days 1 to 6) and convalescent (days 14
to 28) phases, as well as 3, 6, 12, and 18 months post-onset of illness.
(ii) Pediatric Dengue Cohort Study. The Nicaraguan Pediatric Dengue Cohort Study (PDCS; 2004 to
present) is a community-based prospective study of approximately 3,500 children 2 to 14 years of age
in Managua, Nicaragua (36). Healthy annual blood samples collected from 10 participants 1, 2, 3, and
4 years after experiencing a primary DENV3 infection were used.
Laboratory tests. DENV infection was confirmed by RT-PCR for detection of viral RNA (37, 38),
isolation of DENV on C6/36 cells (37), and/or seroconversion by IgM enzyme-linked immunosorbent assay
(ELISA) or a 4-fold increase in total antibody titer as measured by inhibition ELISA in paired acute- and
convalescent-phase samples. In the hospital study, primary dengue cases were determined by inhibition
ELISA (39, 40), where antibody titers of 2,560 in the convalescent-phase sample (day 14 to 28
post-onset of symptoms) define primary infection status (13). In the cohort study, a primary DENV
infection was classified by seroconversion (a titer of 1:10 to 1:10 as determined by inhibition ELISA)
in paired consecutive annual samples (36).
Cells and viruses. U937 cells expressing DC-SIGN (dendritic cell-specific intercellular adhesion
molecule-3-grabbing nonintegrin), a known DENV attachment factor, were maintained as suspension cell
cultures at 37°C with 5% CO2 in RPMI 1640 (Gibco) supplemented with 1% non-essential amino acids, 1%
penicillin and streptomycin, and 5% fetal bovine serum (FBS; HyClone). Aedes albopictus C6/36 cells were
grown at 32°C in 5% CO2 and were used for propagation of the Nicaraguan strains of DENV1 (N1265),
DENV2 (N172), and DENV3 (N7236), parental strains of DENV3 (UNC 3001) and DENV4 (Haiti 74), and
recombinant viruses rDENV4/3-M14 and rDENV4/3-M16. The rDENV4/3-M14 virus contains 29 amino acid
residues within the 5J7 epitope, spanning two E protein monomers, whereas the rDENV4/3-M16 virus
contains 36 amino acid residues from the 5J7 epitope spanning three E protein monomers (Widman et
al., unpublished).
DENV neutralization assay. A flow cytometry-based neutralization assay was used to measure
DENV-specific neutralizing antibodies, as previously described (41). Briefly, DENV-immune plasma at an
initial dilution of 1:5 were serially diluted 3-fold 8 times in RPMI supplemented with 2% FBS. An amount
of virus that infects 15% of the cells (previously determined by virus titration) was added to the plasma
dilutions and incubated for 45 min at 37°C. After 24 h, the cells were centrifuged at 252  g for 5 min
and resuspended in 100 l of RPMI medium. Next, cells were fixed in 4% paraformaldehyde, incubated
for 10 min at room temperature, and centrifuged at 252  g for 5 min. Then, cells were blocked in
permeabilization buffer (0.1% saponin, 5% bovine serum albumin in 1 phosphate-buffered saline [PBS])
for 30 min at room temperature. Cells were subsequently incubated with anti-E MAb 4G2 conjugated to
Alexa 488, diluted 1:1,000 in blocking buffer (0.5% bovine serum albumin and 0.02% sodium azide in 1
PBS) for 25 min at room temperature. Cells were washed and resuspended in PBS. The percentage of
infected cells was determined using a Guava flow cytometer (EMD Millipore) by gating Alexa 488-positive
cells. The plasma dilution that reduced viral infection by 50% (50% neutralizing antibody titer [NT50]) was
calculated by a nonlinear, 4-parameter dose-response regression analysis with Prism software (Graph-
Pad), which is expressed as the reciprocal serum dilution. To eliminate the effect of nonspecific
cross-reactivity in human plasma, DENV-naïve titers (average of 10 DENV-naïve individuals enrolled in the
PDCS) were subtracted from DENV-immune titers. Quality control criteria for the sigmoidal dose-
response regression fit included an absolute sum of squares of 0.2 and a coefficient of determination
(R2) of 0.9.
Antigenic cartography map. Antigenic maps were generated from NT50 against DENV3 UNC 3001,
DENV4 Haiti 74, and rDENV4/3-M14 obtained from antisera collected at 3 and 18 months post-infection,
as previously described (42). The measured antigenic distance, Dij, between virus i and antiserum j was
estimated as Dij  log2(bj)  log2(Nij), where bj is the NT50 titer for the virus best neutralized by each
antiserum j, and Nij is the NT50 for virus i and antiserum j. Error function, E  ije(Dij, dij), was minimized
(5,000 independent optimizations) to estimate coordinates for viruses and antisera that produced
antigenic maps with the least disagreement between Euclidean distances, dij, and measured antigenic
distances, Dij. Error was defined as e(Dij, dij)  (Dij  dij)2 when the NT50 was within the limit of detection
of the assay and e(Dij, dij)  (Dij  1  dij)2{1/[1  e10(dij  1  dij)]} for NT50 values below the assay limit
of detection. The minimum error antigenic map is shown on a grid indicating antigenic distances as
2-fold dilutions, in any direction, on the antigenic map. The shift in virus position from the 3- to 18-month
maps is shown with arrows.
Statistical analysis. Statistical analysis was conducted using Prism Graph Pad 5.0 (La Jolla, CA) and
R (version 3.1.3). Two-way analysis of variance (ANOVA) was used to compare the NT50 values to
rDENV4/3, DENV3 and DENV4 viruses at 3 and 18 months post-illness. Linear regression analysis with
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Pearson coefficient was used to evaluate the correlation between rDENV4/3 virus and DENV3 or DENV4
at 3 and 18 months post-illness. The paired t test was used for comparing the proportions of the DENV3
neutralizing antibody response attributable to the 5J7 epitope between samples collected 3 and
18 months postillness. A P value of 0.05 was accepted as statistically significant.
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